1-2 of 2
Atsushi Suzuki
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

Keiichi Sakakibara, Naoya Saito, Takuji Sato, Atsushi Suzuki, Yoko Hasegawa, Jonathan M. Friedman, Donald W. Kufe, Daniel D. VonHoff, Tadahiko Iwami, Takumi Kawabe
Journal: Blood
Blood (2011) 118 (14): 3922–3931.
https://doi.org/10.1182/blood-2011-01-333138
Published: 2011
Includes: Supplemental data
Journal Articles

Overexpression of Carboxylesterase-2 Results in Enhanced Efficacy of Topoisomerase I Inhibitor, Irinotecan (CPT-11), for Refractory Multiple Myeloma.

Hiroki Yano, MD, Satoshi Kayukawa, M.D., Shinsuke Iida, M.D., Chiharu Nakagawa, Ph.D., Takaomi Sanda, M.D. Ph.D., Shigeru Kusumoto, M.D., Takashi Ishida, M.D. Ph.D., Hirokazu Komatsu, M.D., Atsushi Suzuki, Ph.D., Ryuzo Ueda, M.D.
Journal: Blood
Blood (2006) 108 (11): 5107.
https://doi.org/10.1182/blood.V108.11.5107.5107
Published: 2006